Belantamab mafodotin – Uses, Dosage, Side Effects, Interactions

Belantamab mafodotin is an anti-B-cell maturation antigen-antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma. Belantamab mafodotin, or GSK2857916, is a fucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).^[rx]Belantamab mafodotin was granted FDA approval on 5 August 2020.

Mechanism of action

Belantamab mafodotin is a humanized IgG1κ monoclonal antibody against the B-cell maturation antigen (BCMA) conjugated with a cytotoxic agent, maleimidocaproyl monomethyl auristatin F (mcMMAF).^[rx] The antibody-drug conjugate binds to BCMA on myeloma cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity.^[rx]

Belantamab mafodotin, or GSK2857916, is a fucosylated monoclonal antibody that targets B cell maturation antigen (BCMA) conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).^[rx] Afucosylation of the Fc region of monoclonal antibodies enhances binding to the Fc region, which enhances antibody-dependant cell-mediated cytotoxicity.^[rx]

BCMA is uniquely expressed in CD138-positive myeloma cells.^[rx] Targeting BCMA allows belantamab mafodotin to be highly selective in its delivery of MMAF to multiple myeloma cells^[rx] Belantamab mafodotin binds to BCMA, is internalized into cells, and releases MMAF.^[rx]

The MMAF payload binds to tubulin, stopping the cell cycle at the DNA damage checkpoint between the G2 and M phases, resulting in apoptosis.^[rx]

Belantamab mafodotin treats multiple myeloma through antibody dependant cell-mediated cytotoxicity as well as G2/M cell cycle arrest.^[rx] It has a narrow therapeutic index due to the incidence of adverse effects, and a long duration of action as it is given every 3 weeks.^[rx] Patients should be counseled regarding the risk of keratopathy.^[rx]

Indication

• Belantamab mafodotin is indicated in the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.^[rx]
• Relapsed Or Refractory Multiple Myeloma
• Belantamab mafodotin is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
• For treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Use in Cancer

Belantamab mafodotin-blmf is approved to treat:

• Multiple myeloma that has relapsed (come back) or is refractory (does not respond to treatment). It is used in adults who have received at least four previous treatments that included an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulating agent.

Belantamab mafodotin-blmf is only available as part of a special program called Blenrep REMS (Risk Evaluation and Mitigation StrategiesExit Disclaimer).

This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that belantamab mafodotin-blmf provides a clinical benefit in these patients.

Contraindication

The following conditions are contraindicated with this drug. Check with your physician if you have any of the following:

• decreased blood platelets
• a decrease in sharpness of vision called reduced visual acuity
• pregnancy
• a patient who is producing milk and breastfeeding

Dosage

Strengths: blmf 100 mg

Multiple Myeloma

• 2.5 mg/kg (of actual body weight) IV over 30 minutes once every 3 weeks until disease progression or unacceptable toxicity

Renal Dose Adjustments

• Mild (CrCl 60 to less than 90 mL/min) or moderate (CrCl 30 to less than 60 mL/min) renal impairment: No adjustment recommended.
  Severe (CrCl 15 to less than 30 mL/min) or end-stage (CrCl less than 15 mL/min) renal impairment: Data not available

Liver Dose Adjustments

• Mild hepatic impairment (total bilirubin less than or equal to the upper limit of normal [ULN] and aspartate aminotransferase (AST) greater than ULN or total bilirubin 1 to less than or equal to 1.5 x ULN and any AST): No adjustment recommended.
  Moderate or severe hepatic impairment (total bilirubin greater than 1.5 x ULN and any AST): Data not available

Dose Adjustments

DOSE MODIFICATIONS FOR ADVERSE REACTIONS:

• The recommended dose reduction for adverse reactions is: 1.9 mg/kg IV once every 3 weeks; discontinue therapy in patients who are unable to tolerate a dose of 1.9 mg/kg.

CORNEAL ADVERSE REACTIONS:

• The recommended dosage modifications for corneal adverse reactions are based on both corneal examination findings and changes in best-corrected visual acuity (BCVA).
• Determine the dose modification based on the worst finding in the worst affected eye. Worst finding should be based on either a corneal examination finding or a change in visual acuity per the Keratopathy and Visual Acuity (KVA) scale.

DOSE MODIFICATIONS FOR CORNEAL ADVERSE REACTIONS PER THE KVA SCALE CORNEAL ADVERSE REACTION:

• GRADE 1 (mild superficial keratopathy with or without symptoms; change in BCVA: decline from baseline of 1 line on Snellen Visual Acuity: Continue therapy at the current dose.
• GRADE 2: (moderate superficial keratopathy with or without patchy microcyst-like deposits, sub-epithelial haze [peripheral], or a new peripheral stromal opacity; change in BCVA: decline from baseline of 2 or 3 lines on Snellen Visual Acuity and not worse than 20/200): Withhold therapy until improvement in both corneal examination findings and change in BCVA to Grade 1 or less; resume at the same dose.
• GRADE 3 (severe superficial keratopathy with or without diffuse microcyst-like deposits, sub-epithelial haze (central), or a new central stromal opacity; change in BCVA: decline from baseline of 2 or 3 lines on Snellen Visual Acuity and not worse than 20/200): Withhold therapy until improvement in both corneal examination findings and change in BCVA to Grade 1 or less; resume at a reduced dose.
• GRADE 4 (corneal epithelial defect [e.g., corneal ulcers]; change in BCVA: Snellen Visual Acuity worse than 20/200): Consider permanent discontinuation of therapy; if continuing therapy, withhold this drug until improvement in both corneal examination findings and change in BCVA to Grade 1 or better; resume at a reduced dose.

DOSE MODIFICATIONS FOR OTHER ADVERSE REACTIONS:
THROMBOCYTOPENIA:

• Platelet counts 25,000 to less than 50,000/mcL: Consider withholding this drug and/or reducing the dose.
• Platelet count less than 25,000/mcL: Withhold this drug until platelet count improves to Grade 3 or less; consider resuming at a reduced dose.

INFUSION-RELATED REACTIONS:

• GRADE 2 or 3: Interrupt infusion and provide supportive care; when symptoms resolve, resume infusion rate at 50% of the previous rate.
• GRADE 4: Permanently discontinue therapy and provide emergency care.

OTHER ADVERSE REACTIONS:

• GRADE 3: Withhold therapy until improvement to Grade 1 or less; consider resuming at a reduced dose.
• GRADE 4: Consider permanent discontinuation of therapy; if continuing therapy, withhold this drug until improvement to Grade 1 or less and resume at a reduced dose.

Side Effects

The Most Common

• nausea
• constipation
• diarrhea
• loss of appetite
• joint or back pain
• tiredness
• unusual bleeding or bruising
• shortness of breath, chest pain, cough

More common

• Black, tarry stools
• bleeding gums
• blood in urine or stools
• blurred vision or any other change in vision
• body aches or pain
• change in color vision
• chest pain or tightness
• chills
• confusion
• constipation
• cough
• decreased frequency or amount of urine
• depression
• difficulty seeing at night
• difficulty with swallowing
• dizziness
• dry eye
• dry mouth
• ear congestion
• eye redness, irritation, or pain
• fainting
• fast heartbeat

Rare

• fever
• headache
• incoherent speech
• increased sensitivity of the eyes to sunlight
• increased thirst
• increased urination
• lightheadedness or faintness
• loss of appetite
• loss of voice
• low blood pressure or pulse
• lower back or side pain
• metallic taste
• muscle weakness
• nausea
• pinpoint red spots on the skin
• pounding in the ears
• rapid, shallow breathing
• runny or stuffy nose
• skin rash, itching, or hives
• sneezing
• sore throat
• stomach pain
• swelling in the face, hands, or lower legs
• trouble breathing
• unconsciousness
• unusual bleeding or bruising
• unusual tiredness or weakness
• vomiting
• weight gain or loss

Drug Interaction

DRUG	INTERACTION
Abciximab	The risk or severity of adverse effects can be increased when Abciximab is combined with Belantamab mafodotin.
Abemaciclib	The serum concentration of Abemaciclib can be increased when it is combined with Belantamab mafodotin.
Abrocitinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Abrocitinib.
Acetylcysteine	The excretion of Belantamab mafodotin can be decreased when combined with Acetylcysteine.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Belantamab mafodotin.
Aducanumab	The risk or severity of adverse effects can be increased when Aducanumab is combined with Belantamab mafodotin.
Afatinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Afatinib.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Belantamab mafodotin.
Alirocumab	The risk or severity of adverse effects can be increased when Alirocumab is combined with Belantamab mafodotin.
Ambrisentan	The serum concentration of Belantamab mafodotin can be increased when it is combined with Ambrisentan.
Aminohippuric acid	The excretion of Belantamab mafodotin can be decreased when combined with Aminohippuric acid.
Amiodarone	The serum concentration of Belantamab mafodotin can be increased when it is combined with Amiodarone.
Amivantamab	The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Amivantamab.
Amprenavir	The excretion of Belantamab mafodotin can be decreased when combined with Amprenavir.
Anifrolumab	The risk or severity of adverse effects can be increased when Anifrolumab is combined with Belantamab mafodotin.
Ansuvimab	The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Ansuvimab.
Anthrax immune globulin	The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Belantamab mafodotin.
Antilymphocyte immunoglobulin	The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Belantamab mafodotin.
Antithymocyte immunoglobulin	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Belantamab mafodotin.
Apalutamide	The serum concentration of Belantamab mafodotin can be decreased when it is combined with Apalutamide.
Apixaban	The serum concentration of Belantamab mafodotin can be increased when it is combined with Apixaban.
Arsenic trioxide	The serum concentration of Belantamab mafodotin can be increased when it is combined with Arsenic trioxide.
Asciminib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Asciminib.
Asfotase alfa	The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Belantamab mafodotin.
Astemizole	Astemizole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Asunaprevir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Asunaprevir.
Ataluren	The excretion of Belantamab mafodotin can be decreased when combined with Ataluren.
Atazanavir	Atazanavir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Atenolol	Atenolol may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Atezolizumab	The risk or severity of adverse effects can be increased when Atezolizumab is combined with Belantamab mafodotin.
Atoltivimab	The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Atoltivimab.
Atorvastatin	Atorvastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Atropine	Atropine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Avanafil	The serum concentration of Belantamab mafodotin can be increased when it is combined with Avanafil.
Avatrombopag	The serum concentration of Belantamab mafodotin can be increased when it is combined with Avatrombopag.
Avelumab	The risk or severity of adverse effects can be increased when Avelumab is combined with Belantamab mafodotin.
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Belantamab mafodotin.
Bamlanivimab	The risk or severity of adverse effects can be increased when Bamlanivimab is combined with Belantamab mafodotin.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Belantamab mafodotin.
Bebtelovimab	The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Bebtelovimab.
Beclomethasone dipropionate	The excretion of Belantamab mafodotin can be decreased when combined with Beclomethasone dipropionate.
Belimumab	The risk or severity of adverse effects can be increased when Belimumab is combined with Belantamab mafodotin.
Belinostat	The serum concentration of Belantamab mafodotin can be increased when it is combined with Belinostat.
Belumosudil	The serum concentration of Belantamab mafodotin can be increased when it is combined with Belumosudil.
Bempedoic acid	The excretion of Belantamab mafodotin can be decreased when combined with Bempedoic acid.
Bendamustine	The serum concentration of Bendamustine can be increased when it is combined with Belantamab mafodotin.
Benralizumab	The risk or severity of adverse effects can be increased when Benralizumab is combined with Belantamab mafodotin.
Berotralstat	The serum concentration of Berotralstat can be increased when it is combined with Belantamab mafodotin.
Besilesomab	The risk or severity of adverse effects can be increased when Besilesomab is combined with Belantamab mafodotin.
Betrixaban	The serum concentration of Belantamab mafodotin can be increased when it is combined with Betrixaban.
Bevacizumab	The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belantamab mafodotin.
Bezafibrate	The excretion of Belantamab mafodotin can be decreased when combined with Bezafibrate.
Bezlotoxumab	The risk or severity of adverse effects can be increased when Bezlotoxumab is combined with Belantamab mafodotin.
Bimekizumab	The risk or severity of adverse effects can be increased when Bimekizumab is combined with Belantamab mafodotin.
Binimetinib	The serum concentration of Binimetinib can be increased when it is combined with Belantamab mafodotin.
Bisoprolol	The serum concentration of Belantamab mafodotin can be increased when it is combined with Bisoprolol.
Blinatumomab	The risk or severity of adverse effects can be increased when Blinatumomab is combined with Belantamab mafodotin.
Bortezomib	The serum concentration of Bortezomib can be increased when it is combined with Belantamab mafodotin.
Bosentan	Bosentan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Belantamab mafodotin.
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Belantamab mafodotin.
Brodalumab	The risk or severity of adverse effects can be increased when Brodalumab is combined with Belantamab mafodotin.
Brolucizumab	The risk or severity of adverse effects can be increased when Brolucizumab is combined with Belantamab mafodotin.
Budesonide	Budesonide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Burosumab	The risk or severity of adverse effects can be increased when Burosumab is combined with Belantamab mafodotin.
Cabazitaxel	The serum concentration of Cabazitaxel can be increased when it is combined with Belantamab mafodotin.
Cabergoline	The serum concentration of Cabergoline can be increased when it is combined with Belantamab mafodotin.
Canagliflozin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Canagliflozin.
Canakinumab	The risk or severity of adverse effects can be increased when Canakinumab is combined with Belantamab mafodotin.
Caplacizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Belantamab mafodotin.
Capmatinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Capmatinib.
Capromab pendetide	The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Belantamab mafodotin.
Carfilzomib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Carfilzomib.
Carvedilol	The serum concentration of Belantamab mafodotin can be increased when it is combined with Carvedilol.
Casirivimab	The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Casirivimab.
Caspofungin	The excretion of Belantamab mafodotin can be decreased when combined with Caspofungin.
Catumaxomab	The risk or severity of adverse effects can be increased when Catumaxomab is combined with Belantamab mafodotin.
Cefaclor	Cefaclor may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Celecoxib	Celecoxib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Cemiplimab	The risk or severity of adverse effects can be increased when Cemiplimab is combined with Belantamab mafodotin.
Ceritinib	The serum concentration of Ceritinib can be increased when it is combined with Belantamab mafodotin.
Cerivastatin	Cerivastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Certolizumab pegol	The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Belantamab mafodotin.
Cetuximab	The risk or severity of adverse effects can be increased when Cetuximab is combined with Belantamab mafodotin.
Chlorpromazine	Chlorpromazine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Cholecystokinin	The excretion of Belantamab mafodotin can be decreased when combined with Cholecystokinin.
Cholic Acid	Cholic Acid may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Cilgavimab	The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Cilgavimab.
Cimetidine	Cimetidine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Clarithromycin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Clarithromycin.
Clobazam	The serum concentration of Belantamab mafodotin can be increased when it is combined with Clobazam.
Clofazimine	The serum concentration of Belantamab mafodotin can be increased when it is combined with Clofazimine.
Clomifene	The serum concentration of Belantamab mafodotin can be increased when it is combined with Clomifene.
Cobicistat	The serum concentration of Belantamab mafodotin can be increased when it is combined with Cobicistat.
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Belantamab mafodotin.
Colchicine	The serum concentration of Belantamab mafodotin can be increased when it is combined with Colchicine.
Conivaptan	The serum concentration of Belantamab mafodotin can be increased when it is combined with Conivaptan.
Conjugated estrogens	Conjugated estrogens may increase the thrombogenic activities of Belantamab mafodotin.
Copanlisib	The serum concentration of Copanlisib can be increased when it is combined with Belantamab mafodotin.
Crizotinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Crizotinib.

Curcumin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Curcumin.
Cyclosporine	Cyclosporine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Dabigatran etexilate	The serum concentration of Belantamab mafodotin can be increased when it is combined with Dabigatran etexilate.
Dabrafenib	The serum concentration of Dabrafenib can be increased when it is combined with Belantamab mafodotin.
Daclatasvir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Daclatasvir.
Dacomitinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Dacomitinib.
Dactinomycin	The serum concentration of Dactinomycin can be increased when it is combined with Belantamab mafodotin.
Daptomycin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Daptomycin.
Daratumumab	The risk or severity of adverse effects can be increased when Daratumumab is combined with Belantamab mafodotin.
Darolutamide	The serum concentration of Belantamab mafodotin can be increased when it is combined with Darolutamide.
Darunavir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Darunavir.
Dasabuvir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Dasabuvir.
Dasatinib	The serum concentration of Dasatinib can be increased when it is combined with Belantamab mafodotin.
Daunorubicin	Daunorubicin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Belantamab mafodotin.
Deoxycholic acid	Deoxycholic acid may increase the excretion rate of Belantamab mafodotin which could result in a lower serum level and potentially a reduction in efficacy.
Dexamethasone	Dexamethasone may increase the excretion rate of Belantamab mafodotin which could result in a lower serum level and potentially a reduction in efficacy.
Dexamethasone acetate	Dexamethasone acetate may increase the excretion rate of Belantamab mafodotin which could result in a lower serum level and potentially a reduction in efficacy.
Diclofenac	Diclofenac may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Dienestrol	Dienestrol may increase the thrombogenic activities of Belantamab mafodotin.
Diethylstilbestrol	Diethylstilbestrol may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Digitoxin	The serum concentration of Digitoxin can be increased when it is combined with Belantamab mafodotin.
Digoxin	Digoxin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Digoxin Immune	The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Belantamab mafodotin.
Dihydroergocristine	Dihydroergocristine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Dinutuximab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Belantamab mafodotin.
Diosmin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Diosmin.
Dipyridamole	Dipyridamole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Disulfiram	Disulfiram may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Dolutegravir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Dolutegravir.
Dostarlimab	The risk or severity of adverse effects can be increased when Dostarlimab is combined with Belantamab mafodotin.
Doxorubicin	Doxorubicin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Dronedarone	The serum concentration of Belantamab mafodotin can be increased when it is combined with Dronedarone.
Dulaglutide	The risk or severity of adverse effects can be increased when Dulaglutide is combined with Belantamab mafodotin.
Dupilumab	The risk or severity of adverse effects can be increased when Dupilumab is combined with Belantamab mafodotin.
Durvalumab	The risk or severity of adverse effects can be increased when Durvalumab is combined with Belantamab mafodotin.
Duvelisib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Duvelisib.
Ebola Zaire vaccine	The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Belantamab mafodotin.
Eculizumab	The risk or severity of adverse effects can be increased when Eculizumab is combined with Belantamab mafodotin.
Edoxaban	The serum concentration of Belantamab mafodotin can be increased when it is combined with Edoxaban.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Belantamab mafodotin.
Efavirenz	Efavirenz may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Eflapegrastim	The risk or severity of adverse effects can be increased when Eflapegrastim is combined with Belantamab mafodotin.
Eftrenonacog alfa	The risk or severity of adverse effects can be increased when Eftrenonacog alfa is combined with Belantamab mafodotin.
Elagolix	The serum concentration of Belantamab mafodotin can be increased when it is combined with Elagolix.
Elbasvir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Elbasvir.
Elexacaftor	The excretion of Belantamab mafodotin can be decreased when combined with Elexacaftor.
Eliglustat	The serum concentration of Belantamab mafodotin can be increased when it is combined with Eliglustat.
Elotuzumab	The risk or severity of adverse effects can be increased when Elotuzumab is combined with Belantamab mafodotin.
Eltrombopag	The excretion of Belantamab mafodotin can be decreased when combined with Eltrombopag.
Eluxadoline	The excretion of Belantamab mafodotin can be decreased when combined with Eluxadoline.
Emapalumab	The risk or severity of adverse effects can be increased when Emapalumab is combined with Belantamab mafodotin.
Emicizumab	The risk or severity of adverse effects can be increased when Emicizumab is combined with Belantamab mafodotin.
Enasidenib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Enasidenib.
Enfortumab vedotin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Enfortumab vedotin.
Entrectinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Entrectinib.
Eptinezumab	The risk or severity of adverse effects can be increased when Eptinezumab is combined with Belantamab mafodotin.
Erdafitinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Erdafitinib.
Erenumab	The risk or severity of adverse effects can be increased when Erenumab is combined with Belantamab mafodotin.
Ertugliflozin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Ertugliflozin.
Erythromycin	Erythromycin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Esterified estrogens	Esterified estrogens may increase the thrombogenic activities of Belantamab mafodotin.
Estetrol	Estetrol may increase the thrombogenic activities of Belantamab mafodotin.
Estradiol	Estradiol may increase the thrombogenic activities of Belantamab mafodotin.
Estradiol acetate	Estradiol acetate may increase the thrombogenic activities of Belantamab mafodotin.
Estradiol benzoate	Estradiol benzoate may increase the thrombogenic activities of Belantamab mafodotin.
Estradiol cypionate	Estradiol cypionate may increase the thrombogenic activities of Belantamab mafodotin.
Estradiol dienanthate	The excretion of Belantamab mafodotin can be decreased when combined with Estradiol dienanthate.
Estradiol valerate	Estradiol valerate may increase the thrombogenic activities of Belantamab mafodotin.
Estriol	Estriol may increase the thrombogenic activities of Belantamab mafodotin.
Estrone	Estrone may increase the thrombogenic activities of Belantamab mafodotin.
Estrone sulfate	Estrone sulfate may increase the thrombogenic activities of Belantamab mafodotin.
Ethinylestradiol	Ethinylestradiol may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Etoposide	The serum concentration of Etoposide can be increased when it is combined with Belantamab mafodotin.
Everolimus	The serum concentration of Belantamab mafodotin can be increased when it is combined with Everolimus.
Evolocumab	The risk or severity of adverse effects can be increased when Evolocumab is combined with Belantamab mafodotin.
Ezetimibe	Ezetimibe may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Fanolesomab	The risk or severity of adverse effects can be increased when Fanolesomab is combined with Belantamab mafodotin.
Favipiravir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Favipiravir.
Fedratinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Fedratinib.
Felodipine	Felodipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Fenofibrate	Fenofibrate may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Fexofenadine	The serum concentration of Belantamab mafodotin can be increased when it is combined with Fexofenadine.
Filgotinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Filgotinib.
Flibanserin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Flibanserin.
Flucloxacillin	Flucloxacillin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Fluconazole	The serum concentration of Belantamab mafodotin can be increased when it is combined with Fluconazole.
Fluorescein	Fluorescein may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Fluticasone	The excretion of Belantamab mafodotin can be decreased when combined with Fluticasone.
Fluticasone furoate	The excretion of Belantamab mafodotin can be decreased when combined with Fluticasone furoate.
Fluticasone propionate	The excretion of Belantamab mafodotin can be decreased when combined with Fluticasone propionate.
Fluvastatin	The excretion of Belantamab mafodotin can be decreased when combined with Fluvastatin.
Fluvoxamine	Fluvoxamine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Fostemsavir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Fostemsavir.
Fremanezumab	The risk or severity of adverse effects can be increased when Fremanezumab is combined with Belantamab mafodotin.
Fusidic acid	Fusidic acid may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Futibatinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Futibatinib.
Galcanezumab	The risk or severity of adverse effects can be increased when Galcanezumab is combined with Belantamab mafodotin.
Gemcitabine	The serum concentration of Gemcitabine can be increased when it is combined with Belantamab mafodotin.
Gemfibrozil	The excretion of Belantamab mafodotin can be decreased when combined with Gemfibrozil.

Gilteritinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Gilteritinib.
Glasdegib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Glasdegib.
Glecaprevir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Glecaprevir.
Glimepiride	Glimepiride may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Glipizide	Glipizide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Glyburide	Glyburide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Glycyrrhizic acid	Glycyrrhizic acid may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Golimumab	The risk or severity of adverse effects can be increased when Golimumab is combined with Belantamab mafodotin.
Grazoprevir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Grazoprevir.
Guselkumab	The risk or severity of adverse effects can be increased when Guselkumab is combined with Belantamab mafodotin.
Hepatitis B immune	The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Belantamab mafodotin.
cytomegalovirus immune	The risk or severity of adverse effects can be increased when Human cytomegalovirus immune globulin is combined with Belantamab mafodotin.
Human immunoglobulin G	The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Belantamab mafodotin.
Human Rho(D)	The risk or severity of adverse effects can be increased when Human Rho(D) immune globulin is combined with Belantamab mafodotin.
Human varicella-zoster	The risk or severity of adverse effects can be increased when Human varicella-zoster immune globulin is combined with Belantamab mafodotin.
Ibalizumab	The risk or severity of adverse effects can be increased when Ibalizumab is combined with Belantamab mafodotin.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Belantamab mafodotin.
Idarucizumab	The risk or severity of adverse effects can be increased when Idarucizumab is combined with Belantamab mafodotin.
Idelalisib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Idelalisib.
Imatinib	Imatinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Imdevimab	The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Imdevimab.
Imipramine	The serum concentration of Imipramine can be increased when it is combined with Belantamab mafodotin.
Imlifidase	The therapeutic efficacy of Belantamab mafodotin can be decreased when used in combination with Imlifidase.
Indacaterol	The serum concentration of Belantamab mafodotin can be increased when it is combined with Indacaterol.
Indinavir	Indinavir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Indocyanine green acid	Indocyanine green acid form may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Indomethacin	Indomethacin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Inebilizumab	The risk or severity of adverse effects can be increased when Inebilizumab is combined with Belantamab mafodotin.
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Belantamab mafodotin.
Inotuzumab ozogamicin	The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Belantamab mafodotin.
Ipilimumab	The risk or severity of adverse effects can be increased when Ipilimumab is combined with Belantamab mafodotin.
Irinotecan	The excretion of Belantamab mafodotin can be decreased when combined with Irinotecan.
Isatuximab	The risk or severity of adverse effects can be increased when Isatuximab is combined with Belantamab mafodotin.
Isavuconazole	The serum concentration of Belantamab mafodotin can be increased when it is combined with Isavuconazole.
Isavuconazonium	The serum concentration of Belantamab mafodotin can be increased when it is combined with Isavuconazonium.
Isradipine	Isradipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Istradefylline	The serum concentration of Belantamab mafodotin can be increased when it is combined with Istradefylline.
Itraconazole	The serum concentration of Belantamab mafodotin can be increased when it is combined with Itraconazole.
Ivacaftor	The serum concentration of Belantamab mafodotin can be increased when it is combined with Ivacaftor.
Ivermectin	The excretion of Belantamab mafodotin can be decreased when combined with Ivermectin.
Ixabepilone	The serum concentration of Belantamab mafodotin can be increased when it is combined with Ixabepilone.
Ixekizumab	The risk or severity of adverse effects can be increased when Ixekizumab is combined with Belantamab mafodotin.
Ketoconazole	Ketoconazole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Lanadelumab	The risk or severity of adverse effects can be increased when Lanadelumab is combined with Belantamab mafodotin.
Lapatinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Lapatinib.
Larotrectinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Larotrectinib.
Lasmiditan	The serum concentration of Belantamab mafodotin can be increased when it is combined with Lasmiditan.
Ledipasvir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Ledipasvir.
Lefamulin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Lefamulin.
Lemborexant	The serum concentration of Belantamab mafodotin can be increased when it is combined with Lemborexant.
Lenvatinib	Lenvatinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Letermovir	Letermovir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Levocarnitine	The excretion of Belantamab mafodotin can be decreased when combined with Levocarnitine.
Levoketoconazole	The serum concentration of Belantamab mafodotin can be increased when it is combined with Levoketoconazole.
Levothyroxine	The excretion of Belantamab mafodotin can be decreased when combined with Levothyroxine.
Linagliptin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Linagliptin.
Lomitapide	The serum concentration of Belantamab mafodotin can be increased when it is combined with Lomitapide.
Lonafarnib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Lonafarnib.
Loncastuximab tesirine	The serum concentration of Loncastuximab tesirine can be increased when it is combined with Belantamab mafodotin.
Loperamide	The serum concentration of Belantamab mafodotin can be increased when it is combined with Loperamide.
Lopinavir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Lopinavir.
Loratadine	Loratadine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Losartan	Losartan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Lovastatin	Lovastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Loxapine	The serum concentration of Belantamab mafodotin can be increased when it is combined with Loxapine.
Lumacaftor	The serum concentration of Belantamab mafodotin can be decreased when it is combined with Lumacaftor.
Lusutrombopag	The serum concentration of Belantamab mafodotin can be increased when it is combined with Lusutrombopag.
Maftivimab	The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Maftivimab.
Mannitol	The serum concentration of Belantamab mafodotin can be increased when it is combined with Mannitol.
Margetuximab	The risk or severity of adverse effects can be increased when Margetuximab is combined with Belantamab mafodotin.
Maribavir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Maribavir.
Mefloquine	The serum concentration of Belantamab mafodotin can be increased when it is combined with Mefloquine.
Mepolizumab	The risk or severity of adverse effects can be increased when Mepolizumab is combined with Belantamab mafodotin.
Mestranol	Mestranol may increase the thrombogenic activities of Belantamab mafodotin.
Methylene blue	The serum concentration of Belantamab mafodotin can be increased when it is combined with Methylene blue.
Mifepristone	The serum concentration of Belantamab mafodotin can be increased when it is combined with Mifepristone.
Mirabegron	The serum concentration of Belantamab mafodotin can be increased when it is combined with Mirabegron.
Mitapivat	The serum concentration of Belantamab mafodotin can be increased when it is combined with Mitapivat.
Mogamulizumab	The risk or severity of adverse effects can be increased when Mogamulizumab is combined with Belantamab mafodotin.
Morphine	The serum concentration of Belantamab mafodotin can be increased when it is combined with Morphine.
Mosunetuzumab	The risk or severity of adverse effects can be increased when Mosunetuzumab is combined with Belantamab mafodotin.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Belantamab mafodotin.
Naproxen	Naproxen may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Natalizumab	The risk or severity of adverse effects can be increased when Natalizumab is combined with Belantamab mafodotin.
Necitumumab	The risk or severity of adverse effects can be increased when Necitumumab is combined with Belantamab mafodotin.
Nefazodone	Nefazodone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Nelfinavir	Nelfinavir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Neratinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Neratinib.
Netupitant	The serum concentration of Belantamab mafodotin can be increased when it is combined with Netupitant.
Nicardipine	Nicardipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Nifedipine	Nifedipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Nilotinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Nilotinib.
Nintedanib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Nintedanib.
Nitrendipine	Nitrendipine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Nitrofurantoin	Nitrofurantoin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Nivolumab	The risk or severity of adverse effects can be increased when Nivolumab is combined with Belantamab mafodotin.
Norgestimate	The serum concentration of Belantamab mafodotin can be increased when it is combined with Norgestimate.
Nortriptyline	The serum concentration of Nortriptyline can be increased when it is combined with Belantamab mafodotin.
Novobiocin	The excretion of Belantamab mafodotin can be decreased when combined with Novobiocin.

Nystatin	The excretion of Belantamab mafodotin can be decreased when combined with Nystatin.
Obiltoxaximab	The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Belantamab mafodotin.
Obinutuzumab	The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Belantamab mafodotin.
Ocrelizumab	The risk or severity of adverse effects can be increased when Ocrelizumab is combined with Belantamab mafodotin.
Odesivimab	The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Odesivimab.
Ofatumumab	The risk or severity of adverse effects can be increased when Ofatumumab is combined with Belantamab mafodotin.
Ofloxacin	Ofloxacin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Olaratumab	The risk or severity of adverse effects can be increased when Olaratumab is combined with Belantamab mafodotin.
Olmesartan	Olmesartan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Omadacycline	The serum concentration of Belantamab mafodotin can be increased when it is combined with Omadacycline.
Omalizumab	The risk or severity of adverse effects can be increased when Omalizumab is combined with Belantamab mafodotin.
Ombitasvir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Ombitasvir.
Osimertinib	The serum concentration of Osimertinib can be increased when it is combined with Belantamab mafodotin.
Ouabain	The excretion of Belantamab mafodotin can be decreased when combined with Ouabain.
Paclitaxel	Paclitaxel may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Pacritinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Pacritinib.
Palbociclib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Palbociclib.
Paliperidone	The serum concentration of Belantamab mafodotin can be increased when it is combined with Paliperidone.
Palivizumab	The risk or severity of adverse effects can be increased when Palivizumab is combined with Belantamab mafodotin.
Panitumumab	The risk or severity of adverse effects can be increased when Panitumumab is combined with Belantamab mafodotin.
Panobinostat	The serum concentration of Panobinostat can be increased when it is combined with Belantamab mafodotin.
Pantoprazole	The excretion of Belantamab mafodotin can be decreased when combined with Pantoprazole.
Paritaprevir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Paritaprevir.
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Belantamab mafodotin.
Pembrolizumab	The risk or severity of adverse effects can be increased when Pembrolizumab is combined with Belantamab mafodotin.
Pertuzumab	The risk or severity of adverse effects can be increased when Pertuzumab is combined with Belantamab mafodotin.
Pexidartinib	The excretion of Belantamab mafodotin can be decreased when combined with Pexidartinib.
Phenobarbital	Phenobarbital may increase the excretion rate of Belantamab mafodotin which could result in a lower serum level and potentially a reduction in efficacy.
Pibrentasvir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Pibrentasvir.
Pitavastatin	Pitavastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Pitolisant	The serum concentration of Belantamab mafodotin can be increased when it is combined with Pitolisant.
Polatuzumab vedotin	The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Belantamab mafodotin.
Polyestradiol phosphate	Polyestradiol phosphate may increase the thrombogenic activities of Belantamab mafodotin.
Pomalidomide	The serum concentration of Pomalidomide can be increased when it is combined with Belantamab mafodotin.
Ponatinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Ponatinib.
Posaconazole	The serum concentration of Belantamab mafodotin can be increased when it is combined with Posaconazole.
Pralsetinib	Pralsetinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Pravastatin	Pravastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Prednisolone phosphate	The serum concentration of Belantamab mafodotin can be increased when it is combined with Prednisolone phosphate.
Progesterone	Progesterone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Propafenone	The serum concentration of Belantamab mafodotin can be increased when it is combined with Propafenone.
Quinestrol	Quinestrol may increase the thrombogenic activities of Belantamab mafodotin.
Quinidine	Quinidine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Quinine	The serum concentration of Belantamab mafodotin can be increased when it is combined with Quinine.
Ramucirumab	The risk or severity of adverse effects can be increased when Ramucirumab is combined with Belantamab mafodotin.
Ranibizumab	The risk or severity of adverse effects can be increased when Ranibizumab is combined with Belantamab mafodotin.
Ranolazine	The serum concentration of Belantamab mafodotin can be increased when it is combined with Ranolazine.
Ravulizumab	The risk or severity of adverse effects can be increased when Ravulizumab is combined with Belantamab mafodotin.
Raxibacumab	The risk or severity of adverse effects can be increased when Raxibacumab is combined with Belantamab mafodotin.
Regorafenib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Regorafenib.
Relugolix	The serum concentration of Belantamab mafodotin can be increased when it is combined with Relugolix.
Remdesivir	The excretion of Belantamab mafodotin can be decreased when combined with Remdesivir.
Repaglinide	Repaglinide may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Reserpine	Reserpine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Reslizumab	The risk or severity of adverse effects can be increased when Reslizumab is combined with Belantamab mafodotin.
Revefenacin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Revefenacin.
Rifampicin	Rifampicin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Rifamycin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Rifamycin.
Rilpivirine	The excretion of Belantamab mafodotin can be decreased when combined with Rilpivirine.
Rimegepant	The serum concentration of Belantamab mafodotin can be increased when it is combined with Rimegepant.
Riociguat	The serum concentration of Belantamab mafodotin can be increased when it is combined with Riociguat.
Ripretinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Ripretinib.
Risankizumab	The risk or severity of adverse effects can be increased when Risankizumab is combined with Belantamab mafodotin.
Ritonavir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Ritonavir.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Belantamab mafodotin.
Rivaroxaban	The serum concentration of Belantamab mafodotin can be increased when it is combined with Rivaroxaban.
Rolapitant	The serum concentration of Belantamab mafodotin can be increased when it is combined with Rolapitant.
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Belantamab mafodotin.
Romosozumab	The risk or severity of adverse effects can be increased when Romosozumab is combined with Belantamab mafodotin.
Rosiglitazone	Rosiglitazone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Rosuvastatin	Rosuvastatin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Roxadustat	The serum concentration of Belantamab mafodotin can be increased when it is combined with Roxadustat.
Roxithromycin	The excretion of Belantamab mafodotin can be decreased when combined with Roxithromycin.
Sacituzumab govitecan	The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Belantamab mafodotin.
Sacubitril	The excretion of Belantamab mafodotin can be decreased when combined with Sacubitril.
Sapropterin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Sapropterin.
Saquinavir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Saquinavir.
Sarecycline	The serum concentration of Belantamab mafodotin can be increased when it is combined with Sarecycline.
Sarilumab	The risk or severity of adverse effects can be increased when Sarilumab is combined with Belantamab mafodotin.
Secukinumab	The risk or severity of adverse effects can be increased when Secukinumab is combined with Belantamab mafodotin.
Selexipag	The serum concentration of Belantamab mafodotin can be increased when it is combined with Selexipag.
Selinexor	The excretion of Belantamab mafodotin can be decreased when combined with Selinexor.
Selumetinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Selumetinib.
Sildenafil	The serum concentration of Belantamab mafodotin can be increased when it is combined with Sildenafil.
Silodosin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Silodosin.
Siltuximab	The risk or severity of adverse effects can be increased when Siltuximab is combined with Belantamab mafodotin.
Simeprevir	Simeprevir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Simvastatin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Simvastatin.
Sirolimus	The serum concentration of Sirolimus can be increased when it is combined with Belantamab mafodotin.
Sitagliptin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Sitagliptin.
Sofosbuvir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Sofosbuvir.
Sorafenib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Sorafenib.
Sotagliflozin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Sotagliflozin.
Sotorasib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Sotorasib.
Sotrovimab	The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Sotrovimab.
Spesolimab	The risk or severity of adverse effects can be increased when Spesolimab is combined with Belantamab mafodotin.
Spironolactone	Spironolactone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Stiripentol	The excretion of Belantamab mafodotin can be decreased when combined with Stiripentol.
Sulesomab	The risk or severity of adverse effects can be increased when Sulesomab is combined with Belantamab mafodotin.
Sulfamethoxazole	Sulfamethoxazole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.

Sulfasalazine	The excretion of Belantamab mafodotin can be decreased when combined with Sulfasalazine.
Sulfinpyrazone	Sulfinpyrazone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Sutimlimab	The risk or severity of adverse effects can be increased when Sutimlimab is combined with Belantamab mafodotin.
Suvorexant	The serum concentration of Belantamab mafodotin can be increased when it is combined with Suvorexant.
Estrogens, A	Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Belantamab mafodotin.
Estrogens, B	Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Belantamab mafodotin.
Tacrolimus	The serum concentration of Belantamab mafodotin can be increased when it is combined with Tacrolimus.
Tafasitamab	The risk or severity of adverse effects can be increased when Tafasitamab is combined with Belantamab mafodotin.
Talazoparib	The serum concentration of Talazoparib can be increased when it is combined with Belantamab mafodotin.
Tamoxifen	Tamoxifen may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Taurocholic acid	Taurocholic acid may increase the excretion rate of Belantamab mafodotin which could result in a lower serum level and potentially a reduction in efficacy.
Tazemetostat	The serum concentration of Belantamab mafodotin can be increased when it is combined with Tazemetostat.
Technetium	The serum concentration of Belantamab mafodotin can be increased when it is combined with Technetium Tc-99m sestamibi.
Tegaserod	The serum concentration of Belantamab mafodotin can be increased when it is combined with Tegaserod.
Telaprevir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Telaprevir.
Telithromycin	The excretion of Belantamab mafodotin can be decreased when combined with Telithromycin.
Telmisartan	Telmisartan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Temsirolimus	The serum concentration of Belantamab mafodotin can be increased when it is combined with Temsirolimus.
Tenofovir disoproxil	The serum concentration of Belantamab mafodotin can be increased when it is combined with Tenofovir disoproxil.
Tepotinib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Tepotinib.
Terfenadine	Terfenadine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Teriflunomide	The excretion of Belantamab mafodotin can be decreased when combined with Teriflunomide.
Tetanus	The risk or severity of adverse effects can be increased when Tetanus immune globulin, human is combined with Belantamab mafodotin.
Tezacaftor	The serum concentration of Belantamab mafodotin can be increased when it is combined with Tezacaftor.
Tezepelumab	The risk or severity of adverse effects can be increased when Tezepelumab is combined with Belantamab mafodotin.
Tibolone	Tibolone may increase the thrombogenic activities of Belantamab mafodotin.
Ticagrelor	The serum concentration of Belantamab mafodotin can be increased when it is combined with Ticagrelor.
Tildrakizumab	The risk or severity of adverse effects can be increased when Tildrakizumab is combined with Belantamab mafodotin.
Tinidazole	Tinidazole may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Tipranavir	Tipranavir may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Tisotumab vedotin	The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Tisotumab vedotin.
Tivozanib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Tivozanib.
Tixagevimab	The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Tixagevimab.
Tocilizumab	The risk or severity of adverse effects can be increased when Tocilizumab is combined with Belantamab mafodotin.
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Belantamab mafodotin.
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Belantamab mafodotin.
Toremifene	The serum concentration of Belantamab mafodotin can be increased when it is combined with Toremifene.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Belantamab mafodotin.
Tralokinumab	The risk or severity of adverse effects can be increased when Tralokinumab is combined with Belantamab mafodotin.
Trastuzumab	The risk or severity of adverse effects can be increased when Trastuzumab is combined with Belantamab mafodotin.
Trastuzumab deruxtecan	The risk or severity of adverse effects can be increased when Trastuzumab deruxtecan is combined with Belantamab mafodotin.
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be increased when it is combined with Belantamab mafodotin.
Tremelimumab	The risk or severity of adverse effects can be increased when Tremelimumab is combined with Belantamab mafodotin.
Trilaciclib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Trilaciclib.
Trimipramine	The serum concentration of Trimipramine can be increased when it is combined with Belantamab mafodotin.
Troglitazone	Troglitazone may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Tucatinib	Tucatinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Ubrogepant	The serum concentration of Belantamab mafodotin can be increased when it is combined with Ubrogepant.
Umbralisib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Umbralisib.
Umeclidinium	The serum concentration of Belantamab mafodotin can be increased when it is combined with Umeclidinium.
Ursodeoxycholic acid	Ursodeoxycholic acid may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Ustekinumab	The risk or severity of adverse effects can be increased when Ustekinumab is combined with Belantamab mafodotin.
Valsartan	The excretion of Belantamab mafodotin can be decreased when combined with Valsartan.
Vandetanib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Vandetanib.
Vardenafil	The serum concentration of Belantamab mafodotin can be increased when it is combined with Vardenafil.
Vedolizumab	The risk or severity of adverse effects can be increased when Vedolizumab is combined with Belantamab mafodotin.
Velpatasvir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Velpatasvir.
Vemurafenib	The serum concentration of Belantamab mafodotin can be increased when it is combined with Vemurafenib.
Venetoclax	The serum concentration of Belantamab mafodotin can be increased when it is combined with Venetoclax.
Verapamil	The serum concentration of Belantamab mafodotin can be increased when it is combined with Verapamil.
Vinblastine	Vinblastine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Vincristine	Vincristine may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.
Vinflunine	The serum concentration of Vinflunine can be increased when it is combined with Belantamab mafodotin.
Voclosporin	The serum concentration of Belantamab mafodotin can be increased when it is combined with Voclosporin.
Vorapaxar	The serum concentration of Belantamab mafodotin can be increased when it is combined with Vorapaxar.
Voxilaprevir	The serum concentration of Belantamab mafodotin can be increased when it is combined with Voxilaprevir.
Zonisamide	The serum concentration of Belantamab mafodotin can be increased when it is combined with Zonisamide.

Pregnancy and Lactation

 US FDA pregnancy category: Not assigned.

Pregnancy

The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help healthcare providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out. Based on its mechanism of action, this drug can cause fetal harm when administered to a pregnant woman, because it contains a genotoxic compound (the microtubule inhibitor, MMAF) and targets actively dividing cells. Human immunoglobulin G (IgG) is known to cross the placenta; therefore, this drug has the potential to be transmitted from the mother to the developing fetus.

Lactation

There are no data on the presence of this drug in human milk or the effects on the breastfed child or milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during therapy and for 3 months after.

How should this medicine be used?

Belantamab mafodotin-blmf comes as a powder to be mixed with liquid and injected intravenously (into a vein) over 30 minutes by a doctor or nurse in a hospital or medical facility. It is usually given once every 3 weeks. The cycle may be repeated as recommended by your doctor. The length of your treatment depends on how well your body responds to the medication and any side effects that you experience.

A doctor or nurse will watch you closely while you are receiving the medication to be sure you are not having a serious reaction to the medication. Tell your doctor or nurse immediately if you experience any of the following symptoms: chills; flushing; itching or rash; shortness of breath, cough, or wheezing; tiredness; fever; dizziness or lightheadedness; or swelling of your lips, tongue, throat, or face.

Your doctor may reduce your dose or temporarily or permanently stop your treatment. This depends on how well the medication works for you and the side effects you experience. Be sure to tell your doctor how you are feeling during your treatment with belantamab mafodotin-blmf.

What special precautions should I follow?

Before receiving belantamab mafodotin-blmf injection,

• tell your doctor and pharmacist if you are allergic to belantamab mafodotin-blmf, any other medications, or any of the ingredients in belantamab mafodotin-blmf injection. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
• tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
• tell your doctor if you have or have ever had bleeding problems.
• tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. You should not start receiving belantamab mafodotin-blmf injection until a pregnancy test has shown that you are not pregnant. If you are a woman who is able to become pregnant, you must use effective birth control during your treatment and for 4 months after your final dose. If you are male with a female partner who could become pregnant, you must use effective birth control during your treatment and for 6 months after your final dose. Talk to your doctor about methods of birth control that will work for you. If you or your partner become pregnant while receiving belantamab mafodotin-blmf injection, call your doctor. Belantamab mafodotin-blmf injection may harm the fetus.
• tell your doctor if you are breastfeeding. Do not breastfeed during your treatment and for 3 months after your final dose.
• you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of receiving belantamab mafodotin-blmf injection.

When to Contact Your Doctor or Health Care Provider

Contact your health care provider immediately, day or night, if you should experience any of the following symptoms:

• Fever of 100.4º F (38º C) or higher, chills (possible signs of infection)
• Infusion reactions include:
  • Redness of your face
  • Itching or rash
  • Shortness of breath, coughing, or wheezing
  • Swelling of your lips, tongue, throat, or face
  • Dizziness
  • Feel like passing out
  • Tiredness
  • Feel like your heart is racing (palpitations)

• Nausea (interferes with the ability to eat and is unrelieved with prescribed medication)
• Diarrhea (4-6 episodes in a 24-hour period)
• Unusual bleeding or bruising
• Black or tarry stools, or blood in your stools
• Blood in the urine
• Pain or burning with urination
• Extreme fatigue (unable to carry on self-care activities)
• Mouth sores (painful redness, swelling or ulcers)

Always inform your healthcare provider if you experience any unusual symptoms.

References

Show More